XIFAXAN was given a strong recommendation† to treat global IBS-D symptoms in the 2020 ACG Clinical Guideline on Managing IBS5,‡
‡Based on a moderate quality of evidence§
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.